Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard

Publication

Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard

Journal Paper/Review - Nov 2, 2017

Mottet Nicolas, van den Bergh Roderick C N, Rouvière Olivier, van der Poel Henk G, Lam Thomas B, Grummet Jeremy P, Gillessen Sommer Silke, Bourke Liam, Briers Erik, De Santis Maria, Cornford Philip

Citation

Mottet N, van den Bergh R, Rouvière O, van der Poel H, Lam T, Grummet J, Gillessen Sommer S, Bourke L, Briers E, De Santis M, Cornford P. Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. Eur Urol 2017

Type

Journal Paper/Review (English)

Journal

Eur Urol 2017

Publication Date

Nov 2, 2017

Issn Electronic

1873-7560

Brief description/objective

Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.